Evidence map›Paper›PMID 40358628›Full record

Trial reportInternational journal of surgery (London, England)2025

Neoadjuvant chemotherapy with albumin-bound paclitaxel plus cisplatin and capecitabine for locally advanced esophageal squamous cell carcinoma: a phase 2 clinical trial.

Wen Zhang, Xiaowei Chen, Liyan Xue, Zhichao Jiang, Dong Qu, Zhaoyang Yang, Jianjun Qin, Zhen Wang, Miaomiao Zhang, Yong Li and 2 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of surgery (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04390958 (Phase II Study of Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04390958 phase2unknown statusnot on this map

Phase II Study of Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

TypeinterventionalSponsorChinese Academy of Medical SciencesRan2020 to 2022Enrolled70ConditionsEsophageal Squamous Cell CarcinomaArmsnab-paclitaxel, Cisplatin, Capecitabine
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wen ZhangDepartment of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xiaowei ChenDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Liyan XueDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhichao JiangDepartment of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Dong QuDepartment of Imaging Diagnosis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhaoyang YangDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jianjun QinDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhen WangDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Miaomiao ZhangDepartment of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yong LiDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Aiping ZhouDepartment of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shugeng GaoDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant chemotherapy is recommended for locally advanced esophageal squamous cell carcinoma (ESCC), but more effective regimens are needed to improve the outcomes. This study evaluates the efficacy and safety of neoadjuvant chemotherapy with albumin-bound paclitaxel plus cisplatin and capecitabine (APC regimen) for locally advanced ESCC. MATERIALS AND

methodsThis prospective single-center phase 2 clinical study involved patients with locally advanced ESCC (T2-4aN±M0) from May 19, 2020 to September 1, 2022. Patients received neoadjuvant chemotherapy with APC regimen for four cycles and then underwent radical esophagectomy. The primary endpoints were the pathologically complete response (pCR) rate. The secondary endpoints were the major pathological response (MPR) rate, radical resection rate (R0 resection rate), disease-free survival (DFS), event-free survival (EFS), overall survival (OS), and safety.

resultsEighty-two patients with locally advanced ESCC were enrolled in the trial. Of the 80 patients who underwent surgery, the R0 resection rate was 100%, and 23 patients achieved pCR, with a pCR rate of 28.7% (95% confidence interval [CI]: 18.8%-38.6%). Fifty patients achieved MPR, with an MPR rate of 62.5% (95% CI: 51.9%-73.1%). The most common grade 3-4 treatment-related adverse events were neutropenia (25.6%), leukocytosis (14.5%), nausea (7.5%), and peripheral neurotoxicity (5.5%). Five patients developed complications within 1 month after surgery, including pneumonia (five patients, 6.3%), anastomotic fistula (one patient, 1.3%), and laryngeal recurrent nerve paralysis (one patient, 1.3%), all of which were grade 2. The local recurrence was observed in 8 (8.5%) patients, and distant metastasis in 10 (12.2%) patients. The 3-year DFS rate was 81.2%, the 3-year EFS rate 77.8%, and the 3-year survival rate 90%.

conclusionNeoadjuvant treatment with APC regimen for locally advanced ESCC achieved excellent pCR rates and a well-tolerated safety profile. This combination chemotherapy could serve as one optional neoadjuvant treatment. (ClinicalTrials.gov: NCT04390958).

Indexed as

Albumin-Bound PaclitaxelAntineoplastic Combined Chemotherapy ProtocolsCapecitabineCisplatinEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaNeoadjuvant TherapyAdultAgedEsophagectomyFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeAlbumin-Bound PaclitaxelCapecitabineCisplatinalbumin-bound paclitaxelesophageal squamous cell carcinomaneoadjuvant chemotherapypathological complete response

Identifiers

PMID40358628
PMCPMC12165542

What OpenQuestion holds

Textmetadata
LicenceCC BY-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.